Clinical trial Recruiting at 4 sites Observational

Evaluating the safety of Bactiseal Catheters in hydrocephalus patients

Official title: A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter

Run by Integra LifeSciences Corporation · NCT06276543 · Data updated 2026-11-12

This study is trying to see if the Bactiseal catheter, used for managing hydrocephalus, is safe and helps prevent infections in patients who had it implanted.

More Hydrocephalus trials

Quick facts

Study typeObservational
SexAll
Enrollment200 (estimated)
SponsorIntegra LifeSciences Corporation
Industry-sponsored
Locations8 sites (Beijing, Beijing Municipality and 7 other locations)
StatusRecruiting
StartedSeptember 29, 2024
Main results expectedJuly 31, 2026
Study endsDecember 31, 2026
Registry record updatedJanuary 27, 2025
Trial IDNCT06276543 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients who have had a Bactiseal catheter implanted for hydrocephalus for at least two years.

Probably not a fit

Patients who are allergic to components of the Bactiseal catheter or have existing infections at the implant site may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety of the Bactiseal catheter, an antibiotic-impregnated device used for hydrocephalus management. It will retrospectively enroll 200 subjects who had the catheter implanted between January 1, 2019, and June 30, 2022, collecting data on adverse events and infections over a two-year period. Information will be gathered from medical records regarding the subjects' general condition, intraoperative details, and any complications encountered. The study is designed to provide insights into the effectiveness and safety of this catheter in preventing infections.

Why it matters

Potential benefit: If successful, this study could enhance the safety and effectiveness of hydrocephalus treatment by reducing infection rates associated with catheter use.

How similar studies have gone: While this study focuses on a specific catheter, similar studies evaluating antibiotic-impregnated devices have shown promising results in reducing infection rates.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. The informed consent is exempted by the Ethics Committee of a research center. Or a subject or his/her legal representative signed the informed consent form (ICF) prior to the enrollment.
2. A subject had an indication suitable to use Bactiseal Catheter.
3. A subject implanted hydrocephalus shunt catheter for at least 2 years at the time of enrollment.

Exclusion Criteria:

1. A subject didn't have an indication suitable to use the catheter.
2. A subject was known to be allergic to a component or ingredient of the catheter to be implanted, including silicone catheter, rifampicin, and clindamycin.
3. According to the comprehensive judgment of an investigator, a subject had an infection of the implant site when the shunt is implanted, such as ventriculitis, meningitis, peritonitis, and local implant skin infection.
4. A subject was simultaneously implanted with another shunt catheter different from Bactiseal Catheter.
5. A subject had a contraindication of the shunt operation.
6. A subject had uncorrected coagulopathy or any bleeding disorder.

Where it's running

  • the 2nd Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    Recruiting
  • the Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
  • Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Completed
  • Beijing Hospital
    Beijing, Beijing Municipality, China
    Completed
Show 2 more locations
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Completed
  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Completed

Study contacts

  • Principal investigator: Nan Bao, MD — Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
  • Study coordinator: Hua Tang, MD
  • Email: hua.tang@integralife.com
  • Phone: 0086 21-63179772

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.